ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.70
+0.09 (1.05%)
At close: Feb 20, 2026, 4:00 PM EST
8.70
0.00 (-0.02%)
After-hours: Feb 20, 2026, 7:59 PM EST
ImmunityBio Employees
ImmunityBio had 673 employees as of September 30, 2025. The number of employees increased by 1 or 0.15% compared to the same quarter last year.
Employees
673
Change
1
Growth
0.15%
Revenue / Employee
$122,667
Profits / Employee
-$518,003
Market Cap
8.57B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 673 | 1 | 0.15% |
| Jun 30, 2025 | 685 | 63 | 10.13% |
| Mar 31, 2025 | 671 | 43 | 6.85% |
| Dec 31, 2024 | 680 | 52 | 8.28% |
| Sep 30, 2024 | 672 | 2 | 0.30% |
| Jun 30, 2024 | 622 | -61 | -8.93% |
| Mar 31, 2024 | 628 | -75 | -10.67% |
| Dec 31, 2023 | 628 | -97 | -13.38% |
| Sep 30, 2023 | 670 | -90 | -11.84% |
| Jun 30, 2023 | 683 | -57 | -7.70% |
| Mar 31, 2023 | 703 | 15 | 2.18% |
| Dec 31, 2022 | 725 | 138 | 23.51% |
| Sep 30, 2022 | 760 | 222 | 41.26% |
| Jun 30, 2022 | 740 | 229 | 44.81% |
| Mar 31, 2022 | 688 | 213 | 44.84% |
| Dec 31, 2021 | 587 | 112 | 23.58% |
| Sep 30, 2021 | 538 | 273 | 103.02% |
| Jun 30, 2021 | 511 | 246 | 92.83% |
| Mar 31, 2021 | 475 | 210 | 79.25% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 816 |
| Arrowhead Pharmaceuticals | 711 |
| Madrigal Pharmaceuticals | 528 |
| Cytokinetics | 498 |
| Halozyme Therapeutics | 423 |
| Vaxcyte | 414 |
| Krystal Biotech | 295 |
IBRX News
- 2 days ago - ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients - Business Wire
- 3 days ago - ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average - Benzinga
- 3 days ago - ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch - Business Wire
- 4 days ago - What's Behind The Jump In ImmunityBio Stock? - Benzinga
- 4 days ago - ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries - Business Wire
- 4 days ago - ImmunityBio: The Story Surrounding Anktiva So Far - Seeking Alpha
- 5 days ago - ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia - Business Wire
- 20 days ago - These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More - Benzinga